Abstract 185P
Background
The impact of etiology on response to immunotherapy in advanced hepatocellular carcinoma (HCC) is being extensively debated. Early clinical trials suggested that PD-1/PD-L1 blockade prolonged survival of viral HCC patients, but not of those with non-viral HCC. However, a recent post-hoc analysis of the IMbrave-150 trial showed atezolizumab plus bevacizumab (AB) to exhibit similar efficacy in viral and non-viral groups. Here we investigated the role of etiology in AB-treated HCC patients in a real-world scenario to consolidate these findings and integrate them with previous comparative studies with lenvatinib.
Methods
We retrospectively analyzed 885 HCC patients treated with first-line AB from Eastern and Western countries, 53.9% having viral and 46.1% non-viral etiology. Baseline clinical and laboratory characteristics were analyzed with uni- and multi-variate models to assess the impact of etiology on overall survival (OS), time to progression (TTP), response rates and to identify prognostic factors in etiology subgroups.
Results
Overall, no statistically significant differences were found in OS (mOS: viral 15.9mo; non-viral 16.3mo), TTP (mTTP: viral 8.3mo; non-viral 7.2mo), and response rates based on etiology. However, certain prognostic factors differed between the two groups. Among patients with viral etiology, eosinophil count positively correlated with OS, while among non-viral patients AST and ALP levels were significantly related to OS. AFP, NLR, and ALBI score were prognostic for both groups. The toxicity profile of AB almost overlaps in the two etiology subgroups.
Conclusions
These findings indicate that underlying etiology does not significantly impact the outcome of HCC patients treated with AB. However, some prognostic factors differ between viral and non-viral patients, with immunological factors being mostly related to the former while metabolic to the latter, supporting potential biological differences. This may also account for different outcomes of AB observed in comparative studies with lenvatinib in etiology subgroups. Prospective and comparative trials stratifying by etiology are warranted to validate these findings and guide clinical practice.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
F. Finkelmeier: Financial Interests, Personal, Speaker, Consultant, Advisor: AbbVie, MSD, Ipsen, Esai and Fresenius. M. Scartozzi: Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, MSD, Merck, BMS, Servier, Eisai, GSK. A. Casadei Gardini: Financial Interests, Personal, Speaker, Consultant, Advisor: MSD, Eisai, Bayer, Bristol Myers Squibb, AstraZeneca and GSK. All other authors have declared no conflicts of interest.
Resources from the same session
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract